Curriculum Vitae Marikki Laiho, M.D., Ph.D.
Curriculum vitae July 26, 2021
Name Marikki K. Laiho, M.D., Ph.D.
DEMOGRAPHIC AND PERSONAL INFORMATION
Current appointment Professor and Director
Vice Chair for Research
Willard and Lillian Hackerman Professor in Radiation Oncology
Departments of Radiation Oncology and Molecular Radiation Sciences and Oncology
The Johns Hopkins University School of Medicine
Personal Data
Department of Radiation Oncology
The Johns Hopkins School of Medicine
1550 Orleans Street, Room 444
Baltimore, MD 21287
Tel: 410-502-9748
FAX: 410-502-2821
E-mail: mlaiho1@jhmi.edu
Education and Training
1980 Matriculation examination, Haukilahden lukio, Espoo, Finland
1983 Bachelor of Medicine, University of Helsinki, Helsinki, Finland
1986 Junior house officer, Clinics of Internal Medicine, Surgery and Children’s Hospital, Helsinki University Central Hospital, Helsinki
1987 Licentiate of Medicine (M.D.), University of Helsinki
1987 Internship, Helsinki Municipal Health Services, Helsinki
1984-88 Doctor of Medical Science (Ph.D.), University of Helsinki, accepted with distinction
1988-89 Postdoctoral fellow, Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA, Laboratory of Joan Massagué, Ph.D.
1989-90 Research Associate, Cell Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, Laboratory of Joan Massagué, Ph.D.
1991 Docent (Senior Lecturer/Reader), Cell Biology, University of Helsinki
2009 Leadership Development Program, Johns Hopkins Medicine, Johns Hopkins University
2014 Master Mentor Program, Johns Hopkins Medicine, Johns Hopkins University
Professional Experience
1983-87 Research and Teaching Assistant, Department of Virology, University of Helsinki
1988-90 Research Associate, Academy of Finland
1990-94 Research and Teaching Assistant, Department of Virology, University of Helsinki
1992-95 Junior Fellow, Academy of Finland
1996-03 Academy Research Fellow (Senior Fellow), Academy of Finland
2001-02 Acting Professor in Cancer Biology, Department of Pathology, University of Helsinki
2003 Senior Scientist, Academy of Finland
2004 Scientific Secretary, Research Council, Faculty of Medicine, University of Helsinki
2005-2012 Director, Biomedicum Imaging Unit, University of Helsinki
2005-2007 Research Professor, Foundation for the Finnish Cancer Institute
2006-2011 Professor in Molecular Cancer Medicine, University of Helsinki
2006-6/2007 Director, Molecular Cancer Biology Program, University of Helsinki
2006-8/2007 Coordinator, Helsinki Functional Imaging Center, Helsinki
8/2007-7/2008 Visiting Professor and Director, Division of Molecular Radiation Sciences, Department of Radiation Oncology, The Johns Hopkins University School of Medicine
7/2008-present Professor and Director, Division of Molecular Radiation Sciences, Department of Radiation Oncology and Department of Oncology, The Johns Hopkins University School of Medicine
2008- Member, SKCCC, Chemical Therapeutics Program
2008- Member, Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University
2009- Member, Graduate Program in Pathobiology, Johns Hopkins University
2011- Co-Director, SKCCC Developing Program on DNA Damage Biology
2012- Co-Director, SKCCC Experimental Irradiators Core Facility
2016- Professor in Pharmaceutical Cell and Molecular Biology (10% effort) Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
2017- Vice Chair for Research, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine
2019- Co-Leader, Chemical and Structural Biology Program, SKCCC
PUBLICATIONS
Citations as of April 1, 2021
Peer-reviewed Original Research
1. Saksela O, Laiho M, Keski-Oja J. Regulation of plasminogen activator activity in human fibroblastic cells by fibrosarcoma cell-derived factors. Cancer Res. 45: 2314-2319, 1985. Citations:17
2. Alitalo K, Saksela K, Winqvist R, Alitalo R, Keski-Oja J, Laiho M, Ilvonen M, Knuutila S, de la Chapelle A. Acute myelogenous leukemia with c-myc amplification and double minute chromosomes. Lancet 8463: 1035-1039, 1985. Citations:84
3. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-ß alters plasminogen activator activity in human skin fibroblasts. Exp. Cell. Res. 164: 399-407, 1986. Citations:111
4. Keski-Oja J, Laiho M, Vartio T. Characterization of a novel gelatin-binding 21 kDa protein secreted by cultured adherent cells. Biochim. Biophys. Acta 882: 367-376, 1986. Citations:8
5. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-ß. J. Cell. Biol. 103: 2403-2410, 1986. Citations:435
6. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Danø K. Transforming growth factor-ß is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J. 5: 1281-1286, 1987. Citations:258
7. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-ß-induction of type-1 plasminogen activator inhibitor: Pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem. 262: 17467-17474, 1987. Citations:276
8. Laiho M. Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors: Relationships to transforming growth factor-ß. Exp. Cell. Res. 176: 297-308, 1988. Citations:10
9. Anklesaria P, Teixido J, Laiho M, Pierce J, Greenberger JS, Massagué J. Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proc. Natl. Acad. Sci. USA 87: 3289-3293, 1990. Citations:255
10. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J. Growth inhibition by TGF-ß linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185, 1990. Citations:846
11. Laiho M, Weis FMB, Massagué J. Concomitant loss of transforming growth factor-ß receptor types I and II in TGF-ß-resistant cell mutants implicates both receptor types in signal transduction. J. Biol. Chem. 265: 18518-18524, 1990. Citations:316
12. Cheifetz S, Hernandez H, Laiho M, ten Tijke P, Iwata KK, Massagué J. Distinct transforming growth factor-ß (TGF-ß) receptor subsets as determinants of cellular responsiveness to three TGF-ß isoforms. J. Biol. Chem. 265: 20533-20538, 1990. Citations:326
13. Laiho M, Rönnstrand L, Heino J, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J. Control of junB and extracellular matrix protein expression by transforming growth factor-ß1 is independent of SV40 T antigen sensitive growth inhibitory effects. Mol. Cell. Biol. 11: 972-978, 1991. Citations:107
14. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massagué J. Responsiveness to transforming growth factor-ß restored by genetic complementation between cells defective in TGF-ß receptors I and II. J. Biol. Chem. 266: 9108-9112, 1991. Citations:248
15. Zentella A, Weis FMB, Ralph DA, Laiho M, Massagué J. Early gene responses to transforming growth factor-ß in cells lacking RB function. Mol. Cell. Biol. 11: 4952-4958, 1991. Citations:119
16. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massagué J. TGF-ß signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992. Citations:1429
17. Pitkänen K, Kivinen L, DeCaprio JA, Laiho M. Expression of the human retinoblastoma gene product in mouse fibroblasts: Effects on cell proliferation and susceptibility to transformation. Exp. Cell. Res. 207: 99-106, 1993. Citations:11
18. Kivinen L, Pitkänen K, Laiho M. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts. Oncogene 8: 2703-2711, 1993. Citations:9
19. ten Dijke P, Yamashita H, Ichijo H, Franzén P, Laiho M, Miyazono K, Heldin CH. Characterization of type I receptors for transforming growth factor-beta and activin. Science 264: 101-104, 1994. Citations:512
20. Haapajärvi T, Kivinen L, Pitkänen K, Laiho M. Cell cycle dependent effects of UV-radiation on p53 expression and retinoblastoma protein phosphorylation. Oncogene 11: 151-159, 1995. Citations:43
21. Kivinen L, Tiihonen E, Haapajärvi T, Laiho M. p21ras mediated decrease of the retinoblastoma protein in fibroblasts occurs through growth factor dependent mechanisms. Cell Growth Differ. 7: 1705-1712, 1996. Citations:3
22. Haapajärvi T, Pitkänen K, Tsubari M, Laiho M. p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. Mol. Cell. Biol. 17: 3074-3080, 1997. Citations:34
23. Enholm B, Paavonen K, Ristimäki A, Kumar V, Klefström J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNAs regulation by serum, growth factors, oncoproteins, and hypoxia. Oncogene 14: 2475-2483, 1997. Citations:367
24. Tsubari M, Tiihonen E, Laiho M. Cloning and characterization of p10, an alternative spliced form of p15 CDK-inhibitor. Cancer Res. 57: 2966-2973, 1997. Citations:26
25. Pitkänen K, Haapajärvi T, Laiho M. UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation. Oncogene 16: 459-469, 1998. Citations:18
26. Haapajärvi T, Pitkänen K, Laiho M. Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ. 10: 163-171, 1999. Citations:51
27. Tsubari M, Taipale J, Tiihonen E, Keski-Oja J, Laiho M. Hepatocyte growth factor releases mink epithelial cells from transforming growth factor-ß1 induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2-activity. Mol. Cell. Biol. 19: 3654-3663, 1999. Citations:31
28. Haapajärvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF, Laiho M. UV-radiation is a transcriptional inducer of p21Cip1/Waf1 cyclin kinase inhibitor in a p53 independent manner. Exp. Cell Res. 248: 272-279, 1999. Citations:57
29. Kivinen L, Laiho M. Ras and mitogen-activated protein kinase-dependent and independent pathways in p21Cip1/Waf1 induction by FGF-2, PDGF and TGF-ß. Cell Growth Differ. 10: 621-628, 1999. Citations:33
30. Kivinen L, Tsubari M, Haapajärvi T, Datto MB, Wang XF, Laiho M. Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene 18: 6252-6261, 1999. Citations:59
31. Taipale M, Tiihonen E, Heiskanen A, Laiho M. Accumulation of a form of p27Kip1 not associated with Cdk-cyclin complexes in transforming growth factor-ß arrested Mv1Lu cells. Exp. Cell Res. 259: 107-116, 2000. Citations:3
32. Zhang F, Taipale M, Heiskanen A, Laiho M. Ectopic expression of Cdk6 circumvents transforming growth factor-ß mediated growth inhibition. Oncogene 20: 5888-5896, 2001. Citations:7
33. Latonen L, Taya Y, Laiho M. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HMD2 interaction in human fibroblasts. Oncogene 20: 6784-6793, 2001. Citations:95
34. Buzek J, Latonen L, Kurki S, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res. 30: 2340-2348, 2002. Citations:83
35. Zhang F, Mönkkönen M, Roth S, Laiho M. Proteasomal activity modulates TGF-ß signaling in a gene-specific manner. FEBS Lett. 527: 58-62, 2002. Citations:15
36. Zhang F, Mönkkönen M, Roth S, Laiho M. TGF-ß induced G1 cell cycle arrest requires the activity of the proteasome pathway. Exp. Cell. Res. 281: 190-196, 2002. Citations:14
37. Latonen L, Kurki S, Pitkänen K, Laiho M. p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV-radiation and proteasome dysfunction. Cell. Signal. 15: 95-102, 2003. Citations:31
38. Zhang F, Lundin, M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H, Laiho M. Ski-related novel protein N (SnoN), a negative controller of TGF-ß signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 63: 5005-5010, 2003. Citations:73
39. Gentile M, Latonen L, Laiho M. Cell cycle arrest and apoptosis provoked by UV radiation-induced DNA damage are transcriptionally highly divergent responses. Nucleic Acids Res. 31: 4779-4790, 2003. Citations:108
40. Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell. Sci. 116: 3917-3925, 2003. Citations:72
41. Kurki S, Peltonen K, Latonen L, Kiviharju T, Ojala PM, Meek D, Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465-475, 2004. Citations:306
42. Vaque JP, Navascues J, Shiio Y, Laiho M, Ajenjo N, Mauleon I, Matallanas D, Crespo P, Leon J. Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J. Biol. Chem. 280: 1112-1122, 2005. Citations:35
43. von Willebrand M, Köhler K, Alanko T, Laiho M, Saksela, O. FGF-2 blocks TGF-ß1 –mediated suppression of Bcl-2 in normal melanocytes. Exp. Dermatol. 14: 202-208, 2005. Citations:8
44. Peltonen K, Kiviharju T, Järvinen P, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res. 18: 196-202, 2005. Citations:29
45. Laine H, Doetzlhofer A, Mantela J, Ylikoski J, Laiho M, Roussel M, Segil N, Pirvola U. p19Ink4d and p21Cip1 collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis. J. Neurosci. 27: 1434-1444, 2007. Citations:78
46. Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117: 1019-1028, 2007. Citations:104
47. Kiviharju-af Hällström T, Jäämaa S, Mönkkönen M, Peltonen K, Andersson LC, Medema R, Peehl D, Laiho M. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. USA 104: 7211-7216, 2007.
Citations:53
48. Koopal S, Furuhjelm JH, Järviluoma A, Jäämaa S, Pyakurel P, Pussinen C, Wirzenius M, Biberfeld P, Alitalo K, Laiho M, Ojala PM. Viral oncogene-induced DNA damage response is activated in Kaposi’s sarcoma tumorigenesis. PLoS Pathog. 3: 1348-1360, 2007.
Citations:85
49. Latonen L, Järvinen P, Laiho M. Cytoskeleton-interacting LIM-domain protein CRP1 suppresses cell proliferation and protects from stress-induced cell death. Exp. Cell Res. 314: 738-747, 2008. Citations:17
50. Band AM, Björklund M, Laiho M. The phosphatidylinositol 3-kinase/Akt pathway regulates transforming growth factor-ß signaling by de-stabilizing Ski and inducing Smad7. J. Biol. Chem. 284: 35441-35449, 2009. Citations:21
51. Latonen L, Järvinen PM, Suomela, S, Moore HM, Saarialho-Kere U, Laiho M. Ultraviolet B radiation regulates cysteine rich protein 1 in human keratinocytes. Photoderm. Photoimm. Photomed. 26: 70-77, 2010. Citations:7
52. Björklund MA, Vaahtomeri K, Peltonen K, Viollet B, Mäkelä TP, Band AM, Laiho M. Non-CDK-bound p27 (p27NCDK) is a marker for cell stress and is regulated through the Akt/PKB and AMPK-kinase pathways. Exp. Cell Res. 316: 762-774, 2010. Citations:8
53. Sulg M, Kirjavainen A, Pajusola K, Ylikoski J, Bueler H, Laiho M, Pirvola U. Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction. J. Neurochem. 112: 1513-1526, 2010. Citations:12
54. Sarek G, Järviluoma A, Moore HM, Tojkander S, Vartia S, Biberfeld, P, *Laiho M, *Ojala P. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 6: e1000818, 2010. *equal contribution. Citations:54
55. Jäämaa S, af Hällström TM, Sankila A, Rantanen V, Koistinen H, Stenman U, Zhang Z, Yang Z, De Marzo A, Taari K, Ruutu M, Andersson LC, Laiho M. DNA damage recognition via activated ATM and p53 pathway in non-proliferating human prostate tissue. Cancer Res. 70: 8630-8641, 2010. Citations:47
56. Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene 30: 790-805, 2011. Citations:78
57. Peltonen K, Colis L, Liu H, Jäämaa S, Moore HM, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM, Laiho M. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5(9): e12996, 2010. Citations:58
58. Ni X, Zhang Y, Ribas J, Chowdhury WM, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Invest. 121: 2383-2390, 2011. Citations:106
59. Moore HM, Bai B, Boisvert FM, Latonen L, Rantanen V, Simpson JC, Pepperkok R, Lamond AI, Laiho M. Quantitative proteomics and dynamic imaging of the nucleolus reveals distinct responses to UV and ionizing radiation. Mol. Cell. Proteomics 10(10):M111.009241-15, 2011. Citations:76
60. Järvinen PM, Myllärniemi M, Liu H, Moore HM, Latonen L, Leppäranta O, Koli K, Salmenkivi K, Band A, Laiho M. Cysteine-rich protein 1 is regulated by transforming growth factor-ß1 and expressed in lung fibrosis. J. Cell Physiol. 227(6): 2605-2612, 2012.
Citations:9
61. Zhang Z, Yang Z, Jäämaa S, Liu H, Pellakuru LG, Iwata T, af Hällström TM, De Marzo AM, Laiho M. Differential epithelium DNA damage response to ATM and DNA-PK pathway inhibition in human prostate tissue culture. Cell Cycle 10: 3545-3553, 2011. Citations:18
62. Jäämaa S, Sankila A, Rantanen V, Peltonen K, Järvinen P, af Hällström TM, Ruutu M, Taari K, Andersson LC, Laiho M. Contrasting DNA damage checkpoint responses in epithelium of human seminal vesicle and prostate. Prostate 72(10): 1060-1070, 2012. Citations:2
63. Band AM, Laiho M. SnoN oncoprotein enhances estrogen receptor α transcriptional activity. Cell. Signal. 24(4): 922-930, 2012. Citations:10
64. Zhu L, Jäämaa S, af Hällström TM, Laiho M, Sankila A, Nordling S, Stenman UH, Koistinen H. PSA forms complexes with a1-antichymotrypsin in the prostate. Prostate 73(2): 219-226, 2012. Citations:11
65. Bai B, Laiho M. Efficient sequential recovery of nucleolar macromolecular components. Proteomics 12(19-20): 3044-3048, 2012. Citations:7
66. Moore HM, Bai B, Matilainen O, Colis L, Peltonen K, Laiho M. Proteasome activity influences UV-mediated subnuclear localization changes of NPM. PLoS One 8(3): e59096, 2013. Citations:10
67. Bai B, Moore HM, Laiho M. CRM1 and its ribosome export adaptor NMD3 localize to the nucleolus and affect ribosomal RNA synthesis. Nucleus 4(4): 315-325, 2013. Citations:22
68. af Hällström TM, Zhao H, Tian J, Rantanen V, Reese SW, Nolley R, Laiho M, Peehl DM. A tissue graft model of DNA damage response in the normal and malignant human prostate. J. Urology 191(3): 842-849, 2014. Citations:3
69. Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho M. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25: 77-90, 2014. Citations:126
70. Bai B, Liu H, Laiho M. Small RNA expression and deep sequencing analyses of the nucleolus reveal the presence of nucleolus-associated microRNAs. FEBS Open Bio 4: 441-449, 2014. Citations:27
71. Laos M, Anttonen T, Kirjavainen A, af Hällström T, Laiho M, Pirvola U. DNA damage signaling regulates age-dependent proliferative capacity of quiescent inner ear supporting cells. Aging 6(6): 496-510, 2014. Citations:10
72. Colis L, Ernst G, Sanders S, Liu H, Sirajuddin P, Peltonen K, DePasquale M, Barrow JC, Laiho M. Design, synthesis and structure-activity relationships of pyridoquinazoline-carboxamides as RNA polymerase I inhibitors. J. Med. Chem. 57: 4950-4961, 2014. Citations:11
73. Colis L, Peltonen K, Sirajuddin P, Liu H, Sanders S, Ernst G, Barrow JC, Laiho M. DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget 5(12): 4361-4369, 2014. Citations:30
74. Bai B, Yegnasubramanian S, Wheelan SJ, Laiho M. RNA-seq of the nucleolus reveals abundant SNORD44-derived small RNAs. PLoS One 9(9): e107519, 2014. Citations:14
75. Peltonen K, Colis L, Liu H, Jäämaa S, Zhang Z, af Hällström T, Moore HM, Sirajuddin P, Laiho M. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol. Cancer Ther. 13(11): 2537-2546, 2014. Citations:29
76. Balistreri G, Viiliäinen J, Turunen M, Lyly L, Rantala J, Ojala K, Diaz R, Sarek G, Teesalu M, Denisova O, Peltonen K, Julkunen I, Varjosalo M, Kainov D, Kallioniemi O, Laiho M, Taipale J, Hautaniemi S, Ojala PM. Oncogenic Herpesvirus utilizes stress-induced cell cycle checkpoints for efficient lytic replication. PLoS Pathogens 12(2):e1005424, 2016. Citations:18
77. Kara B, Koroglu C, Peltonen K, Steinberg RC, Maras Genç H, Hölttä-Vuori M, Güven A, Kanerva K, Kotil T, Solakoğlu S, Zhou Y, Olkkonen VM, Ikonen E, Laiho M, Tolun A. Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A. Eur. J. Hum. Genet. 25(3): 315-323, 2017. Citations:11
78. Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, af Hällström T, Kulac I, Laiho M*, De Marzo AM*. Novel assay to detect RNA polymerase I activity in vivo. Mol. Cancer Res. 15(5): 577-584, 2017. *Corresponding authors. Citations:5
79. Kilanczyk E, Andres K, Hallgren J, Laiho M, Whittemore SR, Hetman M. Pharmacological inhibition of spinal cord injury-stimulated ribosomal biogenesis does not affect locomotor outcome. Neurosci. Lett. 642: 153-157, 2017. Citations:2
80. Wei T, Najmi SM, Liu H, Peltonen K, Kucerova A, Schneider DA, Laiho M. Small-molecule Targeting of RNA Polymerase I Activates a Novel, Conserved Transcription Elongation Checkpoint. Cell Reports 23: 404-414, 2018. Citations:21
81. Shah AA, Laiho M, Rosen A, Casciola-Rosen L. Scleroderma patients with antibodies against the large subunits of both RNA polymerases-I and -III are protected against cancer. Arthritis Rheumatol. 71(9): 1571-1579, 2019. Citations:13
82. Low JI*, Sirajuddin P*, Moubarek M, Agarwal S, Rege A, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate 79(16):1837-1851, 2019. Citations:3
83. Hämäläinen RH, Landoni JC, Ahlqvist KJ, Goffart S, Ryytty S, Rahman MO, Brilhante V, Icay K, Hautaniemi S, Wang L, Laiho M, Suomalainen A. Defects in mtDNA replication challenge nuclear genome stability through nucleotide depletion and provide a unifying mechanism for mouse progerias. Nature Metabolism 1: 958-965, 2019. Citations:14
84. Low JY, Brennen WN, Meeker AK, Ikonen E, Simons BW, Laiho M. Stromal CAVIN1 controls prostate cancer microenvironment and metastasis by modulating lipid distribution and inflammatory signaling. Mol. Cancer Res. 18(9):1414-1426, 2020. Citations:1
85. Fan W, Eklund E, Sherman RM, Liu H, Pitts S, Ford B, NV Rajeskumar, Laiho M. Widespread germline genetic heterogeneity of human ribosomal RNA genes. BioRxiv 2021. https://doi.org/10.1101/2021.07.21.453267
86. Jacobs RQ, Huffines AK, Laiho M, Schneider DA. BMH-21 directly inhibits transcription elongation and occupancy by RNA polymerase I in vivo and in vitro. Proc. Natl. Acad. Sci. USA Submitted 2021.
87. Claiborne MD, Patel CH, Sun IH, Sun IM, Sengupta S, Zhao L, Arwood ML, Xu W, Wen J, Thompson EA, Mitchell-Flack M, Laiho M, Powell JD. Persistent CAD activity in memory CD8+ T cells supports rRNA synthesis and ribosomal biogenesis required at rechallenge. Sci. Immunol. Submitted 2021.
Peer-reviewed Review Articles
1. Keski-Oja J, Laiho M, Alitalo K. Syöpäsolu kiihdyttää kasvuaan. Tiede 2000 6: 18-21, 1986. (Cancer cell growth control)
2. Keski-Oja J, Laiho M. Kasvutekijät ja kudosvaurioiden paraneminen. Duodecim 104: 1220-1230, 1988. (Growth factors and wound healing)
3. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis of cultured cells. Cancer Res. 49: 2533-2553, 1989. Citations:360
4. Keski-Oja J, Lohi J, Laiho M. Transforming growth factor-ß:s as modulators of pericellular proteolytic events. Cytotechnology 2: 317-332, 1989. Citations:1
5. Saksela O, Laiho M. Kasvutekijät ja soluväliaine. Duodecim 106: 297-306, 1990. (Growth factors and extracellular matrix)
6. Boyd FT, Cheifetz S, Andres J, Laiho M, Massagué J. TGF-ß receptors and binding proteoglycans. J. Cell Sci. Suppl. 13: 131-138, 1990. Citations:31
7. Keski-Oja J, Koli K, Lohi J, Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin. Thromb. Hemost. 17: 231-239, 1991. Citations:46
8. Laiho M, Alitalo K. Kasvurajoitegeenien muutokset syövän syntymekanismina. Duodecim 107: 1680-1691, 1991. (Tumor suppressor genes)
9. Laiho M, Keski-Oja J. Transforming growth factors-ß as regulators of cellular growth and phenotype. Crit. Rev. Oncog. 3: 1-26, 1992. Citations:75
10. Pitkänen K, Tsubari M, Kivinen L, Laiho M. Kasvurajoitegeenit, solusykli ja syöpä. Solubiologi 12: 27-33, 1993. (Tumor suppressor genes, cell cycle and cancer)
11. Latonen L, Laiho M. p53 perimämme vartijana. Solubiologi 17: 15-19, 1999. (p53 as a guardian against genotoxic stress)
12. Laiho M. Miten syöpä syntyy. Duodecim 118: 1751-1758, 2002. (Genesis of cancer)
13. Laiho M, Latonen L. Cell cycle control, DNA damage checkpoints and cancer. Annals Med. 35: 391-397, 2003. Citations:32
14. Zhang F, Laiho M. On and Off: Proteasome and TGF-ß signaling. Exp. Cell Res. 291: 275-281, 2003. Citations:53
15. Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53 - players in UV damage incited nucleolar stress response. Cell Cycle 3: 976-979, 2004. Citations:55
16. Laiho M. Syövän molekyylitason muutokset. Focus Oncologiae 23-26, 2005. (Molecular changes in cancer)
17. Latonen L, Laiho M. Cellular UV damage responses - functions of tumor suppressor p53. BBA Reviews in Cancer 1755: 71-89, 2005. Citations:144
18. Laiho M, Latonen L. Solujen ikääntyminen on taistelua syöpää vastaan. (Senescence as a barrier against cancer). Tiede 3: 20-25, 2008.
19. af Hällström T, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate 68: 902-918, 2008. Citations:23
20. Band AM, Laiho M. Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 16: 109-115, 2011. Citations:52
21. Järvinen PM, Laiho M. LIM-domain proteins in transforming growth factor-beta induced epithelial-to-mesenchymal transition and myofibroblast differentiation. Cell. Signal. 24(4): 819-825, 2012. Citations:22
22. Jäämaa S, Laiho M. Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst. Mol. Oncol. 6(5): 473-483, 2012. Citations:5
23. Wright JL, Alcorn SR, McNutt T, Han-Oh S, Gonzalez R, Lin L, Anderson R, Wieworka J, Deville C, Ladra M, Meyer J, Hales R, Voong R, Narang A, Vogel J, Asrari F, Kiess A, Song D, Tran P, Kleinberg L, Redmond K, Tsien C, Quon H, Page B, Croog V, Walker A, Greco S, Laiho M, Viswanathan A. An Integrated Program in a Pandemic: Johns Hopkins Radiation Oncology Department. Adv. Radiat. Oncol. 5(4):666-672, 2020. Citations:10
Editorials
1. Laiho M. Solusyklin jarrut - uusia kasvunrajoitegeenejä? Duodecim 110: 12-14, 1994. (Cellular brakes - novel tumor suppressor genes?)
2. Latonen L, Laiho M. Kemian Nobelin palkinto proteiinien tuhoamisreitin selvittäjille. Duodecim 120: 2868-2871, 2004. (Nobel Prize in Chemistry to discoverers of the protein destruction pathway)
3. Laiho M, Saksela E. Perimän vauriot, vanheneminen ja syöpä – erottamaton triadi. (DNA damage, senescence and cancer – an uncoupled triad). Duodecim 123: 1535-1536, 2007.
4. Syrjäkari H, Laiho M. Välkettä syvyyksistä – kemian Nobelin palkinto vihreän fluoresoivan proteiinin keksijöille. Duodecim 124: 2599-2601, 2008. (Nobel Prize in Chemistry to the discovery of green fluoresecent protein)
5. Laiho M. Syövän tutkimus Suomessa. (Cancer research in Finland). Duodecim 125: 5-6, 2009.
6. Resar LMS, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M. Equity and diversity in academic medicine: a perspective from the JCI editors. J. Clin. Invest. 129(10): 3974-3977, 2019. Citations:2
Book chapters, monographs
1. Laiho M. Transforming growth factor-ß in the regulation of extracellular proteolysis of cultured cells. University of Helsinki, Helsinki. ISBN 951-99925-6-1 71 pages, 1988.
2. Massagué J, Pandiella A, Laiho M. Growth stimulation by cell to cell contact and growth suppression: Two aspects of the biology of transforming growth factors. In: Cell to Cell Interaction, Karger, Basel, Eds. Burger MM, Sordat B, Zinkernagel RM, pp. 122-142, 1990. Citations:3
3. Massagué J, Heino J, Laiho M. Mechanisms of TGF-ß action. In: Clinical applications of TGF-ß. Wiley, Chichester, CIBA Foundation Symposium 157, pp. 51-65, 1990. Citations:31
4. Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FMB, Zentella A. Transforming growth factor-ß. In: Tumour suppressor genes, the cell cycle and cancer. Ed. A. Levine, Cancer Surveys, vol 12, Imperial Cancer Research Fund, pp. 81-103, 1992. Citations:297
5. Laiho M. Aberrations of DNA damage response and checkpoints in cancer. In: Apoptosis, Cell Signaling and Human Diseases: Molecular Mechanisms. Ed R. Srivastava, Humana Press, 119-136, 2006.
6. Band A, Laiho M. Proteasome in the Control of TGF-ß Signaling During Development and Cancer. In: Transforming growth factor-beta in cancer therapy. Ed. S. Jakowlew, Humana Press, Totowa, NJ, pp. 243-257, 2008. Citations:4
7. Bai B, Laiho M. Sequential Recovery of the Macromolecular Components of the Nucleolus. Methods in Molecular Biology, In: The Nucleus – second edition, Ed. R. Hancock, Springer/Humana Press, 1228: 43-51, 2015. Citations:1
8. Bai B, Laiho M. Deep Sequencing Analysis of Nucleolar Small RNAs: RNA Isolation and Library Preparation. In: The Nucleolus: Methods and Protocols, Ed. A. Nemeth, Springer/Humana Press, 1455: 231-241, 2016.
9. Bai B, Laiho M. Deep Sequencing Analysis of Nucleolar Small RNAs: Bioinformatics. In: The Nucleolus: Methods and Protocols, Ed. A. Nemeth, Springer/Humana Press, 1455: 243-248, 2016.
Books
- Laiho M, Lappalainen M, Saxén L. Molecular biology and biotechnology research in Finland. ISBN 951-715-268-X, 241 pages, 1996.
- DeWeese TL, Laiho M. (Editors) Molecular Determinants of Radiation Response. Springer, New York, NY. ISBN 978-1-4419-8043-4, 276 pages, 2011.
Complete List of Published Work in MyBibliography at NCBI: http://www.ncbi.nlm.nih.gov/sites/myncbi/1fQ2cEVU_MyQn/bibliography/47007621/public/?sort=date&direction=ascending
April 2021: 109 peer-reviewed publications in the Web of Science with 9205 total citations. H-index 42.
FUNDING
Extramural funding
Current:
08/01/2017-07/31/2022 NCE Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
NIH R01 GM121404
$1,445,424 total project direct costs
PI: Laiho
Role: PI, 25% effort
To define novel cellular control networks governing Pol I activity.
09/01/17-09/30/21 A New Paradigm Coupling Stromal Microenvironment to Prostate Cancer Lipid and RNA Synthesis with Therapeutic Application
DoD CDRMP PCRP IDA
$596,157 direct costs
PI: Laiho
Role: PI, 25% effort
To study role of PTRF as a factor that connects lipid metabolism to rRNA synthesis, and test the applicability of lipid metabolism and rRNA synthesis inhibitors in prostate cancer preclinical models.
Previous:
12/17/2017-5/15/2020 Developing of A First-in-Class RNA Polymerase I Inhibitor for Cancer Therapy
Blue One Biosciences LLC
$9,227,840
PI: Laiho
Role: PI, 20% effort
To develop and optimize inhibitors of RNA polymerase I and conduct analyses for patient selection strategies.
09/01/15-08/31/19 Academy of Finland (288364)
RNA polymerase I regulatory functions of a novel small molecule anticancer compound
PI: Laiho
This grant studies the impact of BMH-21 on the structural and functional alterations of the nucleolus using electron microscopy and proteomics analysis.
01/01/16-12/31/18 R21 CA193637-01 Chemogenomic Profiling of a Novel RNA Polymerase I Inhibitor
$275,000 direct costs over two years
PI: Laiho
Role: PI, 10% effort
The application pertains an exploratory study on chemogenomic synthetic lethality screens that exploit cancer cell lethality that arises from inhibition of Pol I transcription.
01/01/15 03/31/18 Development of first-in-kind systemic cancer therapy targeting a major cancer deregulated process
$100,000 direct costs, $148,800 Stage 2 funding
Harrington Scholar-Innovator Award
PI: Laiho
Role: PI, 5% effort
The aims of the project are: To optimize BMH-21-like molecules for clinical candidate selection and to establish efficacy of the new BMH-21 analogs and pharmacodynamic markers for on-target responses.
01/01/14-12/31/18 R01 CA172069 Dual High-Throughput Imaging Screen for Nucleolar Integrity and RNA Transcription
$250,000
PI: Laiho
Role: PI, 25% effort
07/01/16-06/30/17 Development of A Clinical Lead Molecule for RNA Polymerase I
Cigarette Restitution Fund
$50,000 direct costs
PI: Laiho
Role: PI, 1% effort
To test the activity and applicability of new Pol I inhibitory lead molecules.
09/01/16-08/31/17 Lipids Meet RNA Production – A New Paradigm Coupling Stromal Microenvironment to Prostate Cancer Energy Metabolism
Walsh Prostate Cancer Fund
$100,000 direct costs
PI: Laiho
Role: PI, 1% effort
To establish methods and models to study stroma-tumor interactions mediated by a Pol I regulatory protein.
10/01/14 07/31/17 Systemic Treatment For Metastatic Prostate Cancer By A Novel Small
Molecule Targeting RNA Polymerase I
PCF Prostate Cancer Foundation
$500,000 direct costs initial year
PI: Laiho
Role: PI, 5% effort
Demonstrate the unique positioning of a novel anticancer small molecule in co-targeting of RNA polymerase I and AR and its efficacy in treatment of metastatic prostate cancer
04/01/15-03/31/17 Nucleolus: A novel paradigm for PARP1/2 functions and clinical application Allegheny Health Network-Johns Hopkins Cancer Research Fund
$100,000 direct costs initial year
PI: Laiho
Role: PI, 5% effort
The aims of the project are: Aim 1. Define nucleolar PARP1 and PARP2 functions in rRNA biogenesis. Aim 2. Examine synergism by inhibitors of Pol I and PARP1/2.
08/31/11-07/31/15 Academy of Finland (251307)
Mechanisms of action of a novel DNA targeting small-molecule compound
This grant investigates the DNA binding interactions a novel compound.
Role: Principal Investigator
07/15/13-04/14/14 A Novel Cancer Targeting Agent with Special Relevance in Castration-Resistant Prostate Cancer
Maryland Technology Development Corporation
$125,000
PI: Laiho
Role: PI, 10% effort
04/01/12-08/31/14 RNA Polymerase I Inhibition as a Strategy to Curb Prostate Cancer
Patrick C. Walsh Prostate Cancer Research Fund
$75,000
PI: Laiho
Role: PI, 10% effort: share $60,000
09/01/11-31/08/12 Prostate Cancer SPORE (5P50CA58236) Developmental Project (Nelson) Novel small-molecule androgen receptor regulators
The major goal is study how identified lead compounds affect androgen signaling pathway.
Role: Principal Investigator
CLINICAL ACTIVITIES
Certification
1993 Licensed physician, National Board of Medicolegal Affairs, Finland
Service responsibilities
2007 Committee member, Cardiovascular and Metabolic Pharmacology Selection Committee
EDUCATIONAL ACTIVITIES
Teaching
Teaching: Classroom
1983-90 Basic and clinical virology for medical and dentistry students, Teaching assistant, University of Helsinki.
1998 Problem-oriented learning for medical students, Scientific consultant, University of Helsinki.
1998-2007 Molecular and cancer biology course for medical students, Lecturer, University of Helsinki.
Teaching: Workshops and seminars
1990,93 Molecular Biology of Cell Growth, Differentiation and Cancer, University of Helsinki
1992 Basics of Cell Biology, University of Helsinki
1994 Cell Growth and Differentiation, University of Oulu
1997 Regulation of Gene Expression, Biocenter Oulu Graduate School, University of Oulu
1998 Methods in Cell Biology II, Helsinki Biomedical Graduate School, University of Helsinki
1999 Science Fair, Medical Faculty of Helsinki. December 12, 1999. “Cell cycle control and DNA damage repair”.
2000 Clinical Molecular Pathology and Cancer, University of Helsinki. May 18-19, 2000. “p53 mutations and their clinical significance”.
2000 IMT Summer School in Molecular Biology, University of Tampere. August 16-24, 2000. “Cell cycle regulation by transforming growth factor-ß”.
2000 Apoptosis: From Molecular Mechanisms to Therapeutic Applications. Helsinki Biomedical Graduate School, University of Helsinki. September 4-7, 2000. ”p53-mediated cell death”.
2003 Murikka Summer School, Institute of Medical Technology, University of Tampere. Cancer, DNA instability and the Cell Cycle. August 8-10, 2003. “Comparative genomic analysis of cell arrest/death pathways induced by UV damage”.
2004 Advanced Molecular Biology, Helsinki Biomedical Graduate School, University of Helsinki. May 3-6, 2004. “The proteasome-ubiquitin system”.
2005 Biocentrum Helsinki Summer School. “p53 and DNA damage responses”.
2006 Biocentrum Helsinki Summer School. “p53 and DNA damage responses”.
2007 GSBM Course on Cancer Biology. December 11, 2007. “Cellular DNA damage response and Cancer”.
2014 Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 7, 2014. “RNA-seq of the small RNAs in the nucleolus”.
2015 Foundation for Advanced Education in the Sciences, Bethesda, NIH. March 20, 2015. “RNA-seq of the small RNAs in the nucleolus”.
2015 Foundation for Advanced Education in the Sciences, Bethesda, NIH. August 7, 2015. “RNA-seq of the small RNAs in the nucleolus”.
2015 Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 18, 2015. “RNA-seq of the small RNAs in the nucleolus”.
2016 Foundation for Advanced Education in the Sciences, Bethesda, NIH. March 16, 2016. “RNA-seq of the small RNAs in the nucleolus”.
2016 Foundation for Advanced Education in the Sciences, Bethesda, NIH. August 3, 2016. “RNA-seq of the small RNAs in the nucleolus”.
2016 Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 16, 2016. “RNA-seq of the small RNAs in the nucleolus”.
Teaching: Organization of graduate student courses
1995 Practical training course in Essentials of Gene Technology, University of Helsinki, Finland
2002 Advanced Course on Molecular Biology of Cancer, University of Helsinki, Finland
2004 Applications of flow cytometry, University of Helsinki, Finland
2010-12 Genomic Instability in Human Disease, CMM ME:810.716, Johns Hopkins University
Mentoring
Mentoring: Supervision of M.Sc./Ph.D. theses
Name Dates Degree Present Position
Kimmo Pitkänen 1991-99 Ph.D. Director, Helsinki Biobank
Tarja Mälkönen 1993-99 MD.,Ph.D. (Accepted with distinction) Chief Attending, Dermatology, Helsinki and Uusimaa District Hospital, Helsinki
Laura Kivinen 1993-99 MD.,Ph.D. Chief Attending, Internal Medicine, Helsinki and Uusimaa District Hospital, Espoo
Minna Taipale 1993-99 Ph.D. Senior Researcher, Cambrige University, UK
Fan Zhang 2000-03 Ph.D. Post-doctoral fellow, University of British
Columbia
Leena Latonen 1998-03 Ph.D. Assistant Professor, University of Ita-Suomi
Sari Tojkander 2000-07 Ph.D. (Accepted with distinction) Academy Fellow,
University of Helsinki
Taija af Hällström 2003-07 Ph.D. Senior Researcher, Orion, Espoo
Päivi Järvinen 2001-11 Ph.D. Post-doctoral fellow, LMU Klinikum, Munchen
Mia Björklund 2001-20 Ph.D. Manager, Finnish Red Cross
Sari Jäämaa 2001-11 M.D.,Ph.D. Maternity leave
Rishi Trivedi 2011-13 M.Sc. Resident, Johns Hopkins University School of Medicine
Henna M. Moore 2005-13 Ph.D. Research Award Administrator, University of Helsinki
Jhanvi Patel 2013-14 M.Sc. Research Program Assistant, Johns Hopkins University SON
Karita Peltonen 2001-14 Ph.D. Research Manager, University of Helsinki
Brittany Ford 2018- Ph.D. candidate University of Helsinki
Stephanie Pitts 2018- Ph.D. candidate Johns Hopkins University
Mentoring: Post-doctoral
Name Dates Degree Present Position
Stina Roth 2000-02 Ph.D.
Jiri Buzek 1999-01 Ph.D.
Massimiliano Gentile 2002-03 Ph.D. Informatics Director, Blueprint Genetics, Helsinki
Runar Ra 2003-05 Ph.D.
Arja Band 2003-11 Ph.D.
Laureen Colis 2007-13 Ph.D. Scientist, Spark Therapeutics, Philadelphia, PA
Bayoan Bai 2008-13 Ph.D. Postdoctoral fellow, University of Oslo
Zhiming Yang 2008-11 M.D., Ph.D. Staff Pathologist, PathMD, Beverly Hills, CA
Zhewei Zhang 2008-10 M.D. Attending Surgeon, Zhejiang University, Zhejiang
Paul Sirajuddin 2013-16 Ph.D. Scientist, Cepheid, Sunnyvale, CA
Ting Wei 2013-19 Ph.D. Postdoctoral fellow, University of Helsinki
Jin-Yih Low 2017-20 Ph.D. Staff, Fred Hutchinson Cancer Research Center
Asma Begum 2018-20 Ph.D. Research Associate, Johns Hopkins University
Wenjun Fan 2018- Ph.D. Postdoctoral fellow, Johns Hopkins University
Mentoring: thesis committees (member)
Name Dates Degree University
Tiina Santonen 1995-99 Ph.D. University of Turku
Juha Saharinen 1997-99 Ph.D. University of Helsinki
Anneli Hotti 1997-00 Ph.D. University of Helsinki
Anne West 1998-00 Ph.D. University of Turku
Lila Pirkkala 1998-00 Ph.D. University of Turku
Arno Pihlak 1998-00 Ph.D. University of Helsinki
Marika Kärkkäinen 1998-01 Ph.D. University of Helsinki
Päivi Joki-Korpela 1998-01 Ph.D. University of Turku
Miina Weckroth 1998-02 M.D.,Ph.D. University of Helsinki
Tea Vallenius 1999-03 M.D.,Ph.D. University of Helsinki
Marika Häkli 2000-05 Ph.D. University of Helsinki
Annika Järviluoma 2004-07 Ph.D. University of Helsinki
Maria Wirzenius 2004-07 Ph.D. University of Helsinki
Taru Muranen 2004-07 Ph.D. University of Helsinki
Helka Parviainen 2004-11 M.D. University of Helsinki
Mira Heinonen 2005-11 Ph.D. University of Helsinki
Camilla Norrmén 2005-08 Ph.D. University of Helsinki
Yuexi Gu 2010-15 Ph.D. University of Helsinki
Susan Stanley 2013-15 Ph.D. Johns Hopkins University
Alexandra Mims 2013-17 Ph.D. Johns Hopkins University
Ruchama Steinberg 2017-20 Ph.D. Johns Hopkins University
Dimitri Tschelenchuk 2018-21 Ph.D. Johns Hopkins University
Michael Claiborne 2019-21 Ph.D. Johns Hopkins University
Roger Zhou 2020-21 Ph.D. candidate Johns Hopkins University
Emily DeBoy 2020- Ph.D. candidate Johns Hopkins University
Ye Ma 2021- Ph.D. candidate Johns Hopkins University
Pre-examiner of doctoral dissertations
Name Date Degree Field of study/University
Päivi Miettinen 1993 M.D.,Ph.D. developmental biology, University of Helsinki
Anna-Maija Partanen 1993 D.Ds.,Ph.D. developmental biology, University of Helsinki
Sirpa Leppä 1994 M.D.,Ph.D. cell and molecular biology, University of Turku
Tapio Kesti 1994 Ph.D. molecular biology, University of Oulu
Katri Pajusola 1995 Ph.D. molecular cancer biology, University of Helsinki
Anne Vaahtokari 1996 Ph.D. developmental biology, University of Helsinki
Mika Rämet 1998 M.D.,Ph.D. toxicology/ cell biology, University of Oulu
Hesham Attalla 1998 M.D.,Ph.D. cell biology/ endocrinology, University of Helsinki
Maarit Bärlund 1999 M.D.,Ph.D. cancer genetics, University of Tampere
Lila Pirkkala 2000 Ph.D. cell/ molecular biology, University of Turku
Anneli Hotti 2000 Ph.D. cell/ molecular biology, University of Helsinki
Niina Reunanen 2000 M.D.,Ph.D. cell/ molecular biology, University of Turku
Päivi Joki-Korpela 2001 M.D.,Ph.D. virology, University of Turku
Minna Mäkiniemi 2001 Ph.D. biochemistry/molecular biology, University of Oulu
Lea Pylkkänen 2002 Ph.D. genetics and toxicology, University of Joensuu
Pekka Taimen 2004 M.D.,Ph.D. cell/molecular biology, University of Turku
Pia Nyberg 2005 Ph.D. cell/molecular biology, University of Oulu
Teija Aho 2005 Ph.D. cell/molecular biology, University of Turku
Katri Pylkäs 2007 Ph.D. cancer genetics, University of Oulu
Mira Heinonen 2011 Ph.D. cell/ molecular biology, University of Helsinki
Johanna Eriksson 2014 Ph.D. cell/ molecular biology, University of Helsinki
Official examiner of doctoral dissertations (Opponent)
Name Date Degree Field of study/University
Soheil Naderi 1999 Ph.D. cell/molecular biology, University of Oslo, Norway
Jonas Fuxe 2001 Ph.D. cell/molecular biology, Karolinska Institute, Sweden
Song-Ping Li 2003 Ph.D. cell/molecular biology, University of Turku, Finland
Katerina Pardali 2005 Ph.D. cell/molecular biology, University of Uppsala, Sweden
Marie Simonsson 2007 Ph.D. cell/molecular biology, University of Uppsala, Sweden
Adam Ciesiolka 2015 Ph.D. biochemistry, University of Dundee, United Kingdom
Yuan Guo 2020 Ph.D. cell/molecular biology, Stockholm University, Sweden
Referee for docenture promotion
Name Date Degree Field of study/University
Tomi Mäkelä 1996 M.D., Ph.D. cell/molecular biology, University of Helsinki
Marianne Tiainen 2003 Ph.D. cell/molecular biology, University of Helsinki
Nina Nupponen 2006 Ph.D. cell/molecular biology, University of Helsinki
Referee for professorial academic promotions
Associate Professor promotion evaluation 2013, 2017, Johns Hopkins University SOM
Associate Professor promotion evaluation 2015, Roswell Park Cancer Institute, NY
Professor in Molecular Cancer Pharmacology 2015, Karolinska Institutet, Sweden
Professor promotion evaluation 2016, University of Alabama Birmingham, AL
Professor in Cancer Research 2019, University of Turku, Finland
Educational Program Building/Leadership
1994-00 Member, Helsinki Graduate School in Biotechnology Planning and Examination Board
2003,2006 Ad Hoc Reviewer, Helsinki Biomedical Graduate School
2007 Member, Doctoral Program Steering Committee Karolinska Institute-University of Helsinki
Graduate Program Member
1999-2014 Helsinki Biomedical Graduate School, University of Helsinki
2008- Member, Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University
2009- Member, Graduate Program in Pathobiology, Johns Hopkins University
2016- Member, Graduate Program in Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health
2018- Doctoral Program in Drug Research, University of Helsinki
RESEARCH ACTIVITIES
Research Program Building / Leadership
2006-6/2007 Director, Molecular Cancer Biology Program, University of Helsinki
2006-8/2007 Founder and Coordinator, Helsinki Functional Imaging Center, Helsinki
2007- Director, Molecular Radiation Sciences Research Division, Radiation Oncology and Molecular Radiation Sciences
2017- Vice Chair for Research, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine
2019- Co-Leader, Chemical and Structural Biology Program, SKCCC
Inventions, Patents, Copyrights
- Laiho M, Peltonen K. US 8,680,107; US 10,214,491; EU 2195316 (GB, FR, DE, ES, IT); EU 2889297 (GB, FR, DE, ES, IT, IR); Canada 2,691,227; Canada 2,912,456 “Activators and therapeutic applications thereof” 2016-2018. Total 6 granted patents.
- Laiho M, Barrow JA, Colis L, Ernst G, Sanders S. PCT/US2015/021699/15765295/2,943,022 US, EU, Canada “Compounds which inhibit RNA polymerase, compositions including such compounds, and their use” 2014-. 2 granted patents; EU 3119781 (GB, IR, FR, DE, ES, IT); US 11,001,581. 1 pending patent.
- Laiho M, Liu H, Sirajuddin P, Ikonen E. PCT/US2017/052863, 16/335,737, 2017330390, 17853955.7, US, Australia, Canada, Japan, EU “Combinatory treatment strategies of cancer based on RNA polymerase I inhibition” 2016-. Total 5 pending patents.
- Shah AA, Casciola-Rosen L, Rosen A, Igusa T, Laiho M. PCT/US2018/047770 “Screening Method to Identify Scleroderma Immune Responses with Anti-cancer Activity, and Induction of such Immune Responses for Cancer Therapy”.
- Laiho M, Barrow JA, Begum A, Fan W, Liu H, NV Rajesh Kumar, Stachelek G, de Leon P, Dorado T. Provisional patent applications: 63/078,717; 63/078,716; 63/078,723; Compounds which inhibit RNA polymerase, compositions including such compounds, and their use; 9/15/2020.
ORGANIZATIONAL ACTIVITIES
Institutional Administrative Appointments
1993-1995 Member, Governing Board, Department of Virology, University of Helsinki
2006-2007 Director, Molecular Cancer Biology Program, University of Helsinki
2007 Member, Governing Board, Haartman Institute, University of Helsinki
2007- Director, Molecular Radiation Sciences, Radiation Oncology, JHU
2011- Executive, Finance, Clinical Trials and Educational Committees, Radiation Oncology and MRS, JHU
Faculty/University Administrative Appointments
1993-2000 Secretary, Biocentrum Helsinki Governing Board, University of Helsinki
2001 Member, Meilahti Campus Planning Working Group, University of Helsinki
2003 Member and Scientific Secretary, Acting Research Council, Faculty of Medicine, University of Helsinki
2004 Scientific Secretary, Research Council, Faculty of Medicine, University of Helsinki
2005-2007 Vice-Chair, Medicine Fund, Administrative Committee, University of Helsinki
2007 Member, Research Program Governing Board, University of Helsinki
2007 Member, Governing Board, Biocentrum Helsinki, University of Helsinki
2007 Member, University of Helsinki Colloquium
2011 Space Committee, Johns Hopkins University School of Medicine
2012- SKCCC Research Council, Johns Hopkins University School of Medicine
2012-2016 Status of Women Committee, Johns Hopkins University School of Medicine
2014- Research Council, Johns Hopkins University School of Medicine
2016-2018 TAG Therapeutics Committee, Member, Johns Hopkins University School of Medicine
2016- SKCCC New Drug Discovery Committee, Member
2018- Department Director Selection Committee (Radiology, Biological Chemistry, Biophysics and Biophysical Chemistry), Member, Johns Hopkins University School of Medicine
2018- Associate Professor Reappointment Review Committee, Member, Johns Hopkins University School of Medicine
Editorial Activities
Editorial Board appointments
Annals of Medicine 2002-2007
Prostate 2012-
Cancer Research 2016-2019
Journal of Clinical Investigation 2018-
Journal Peer Review Activities
BBA – Molecular Basis of Disease, Ad Hoc Reviewer
British Journal of Cancer, Ad Hoc Reviewer
Cancer Cell, Ad Hoc Reviewer
Cancer Chemical Biology, Ad Hoc Reviewer
Cancer Research, Ad Hoc Reviewer
Carcinogenesis, Ad Hoc Reviewer
Cell Death Differentiation, Ad Hoc Reviewer
Clinical Cancer Research, Ad Hoc Reviewer
DNA Repair, Ad Hoc Reviewer
Duodecim, Ad Hoc Reviewer
Endocrine-Related Cancer, Ad Hoc Reviewer
Experimental Cell Research, Ad Hoc Reviewer
FEBS Letters, Ad Hoc Reviewer
International Journal of Cancer, Ad Hoc Reviewer
International Journal of Radiation Biology, Ad Hoc Reviewer
Journal of Cell Biology, Ad Hoc Reviewer
Journal of Cell Science, Ad Hoc Reviewer
Journal of Clinical Investigation, Ad Hoc Reviewer
Journal of Endocrinology, Ad Hoc Reviewer
Journal of Medicinal Chemistry, Ad Hoc Reviewer
Molecular Cancer Therapeutics, Ad Hoc Reviewer
Molecular and Cellular Biology, Ad Hoc Reviewer
Molecular and Cellular Endocrinology, Ad Hoc Reviewer
Nature Reviews in Cancer, Ad Hoc Reviewer
Nature, Ad Hoc Reviewer
Nature Communications, Ad Hoc Reviewer
Nucleic Acids Research, Ad Hoc Reviewer
Oncogene, Ad Hoc Reviewer
PLoS Genetics, Ad Hoc Reviewer
Proceedings of National Academy of Sciences USA, Ad Hoc Reviewer
Science Signaling, Ad Hoc Reviewer
Advisory Committees, Review Groups
1995-1997 Secretary, MRC Steering Committee for Biotechnology and Molecular Biology,
Academy of Finland
1998-2007 Ad Hoc reviewer, Medical Research Council, Academy of Finland
2002-2007 Member, Advisory Expert Group, National Agency for Medicines, Finland
2004 Ad Hoc reviewer, Austrian Science Fund, Austria
2004 Ad Hoc reviewer, Danish Cancer Society, Denmark
2004 Ad Hoc reviewer, Health Research Council of New Zealand
2004-2006 Ad Hoc reviewer, Wellcome Trust, London, UK
2005 Scientific Secretary, Evaluation of Technomedicum, University of Helsinki
2006 Ad Hoc reviewer, Norwegian Research Council, Norway
2006, 2018 Ad Hoc reviewer, Medical Research Council, UK
2006 Ad Hoc reviewer, LÒreal Foundation, Finland
2007 Ad Hoc reviewer, A*Star Biomedical Research Council, Singapore
2008, 2013,2015 Ad Hoc reviewer, European Research Council
2008, 2013 Ad Hoc reviewer, DoD, CDMRP
2009- Ad Hoc reviewer, ASTRO abstract review committee
2009- Ad Hoc reviewer, The Prostate Cancer Charity, UK
2010, 2017 Ad Hoc reviewer, Dutch Cancer Society, NL
2010, 2011 Ad Hoc reviewer, Cancer Research UK, UK
2012 Ad Hoc reviewer, French National Research Agency, FR
2012, 2014 Ad Hoc reviewer, Samsung Biomedical Research Institute, ROK
2013 Ad Hoc reviewer, Health Research Council of New Zealand, NZ
2013 Ad Hoc reviewer, AICR (Association for International Cancer Research), UK
2014, 2016,2018 Ad Hoc reviewer and panel member, DFG German Research Foundation, GER
2014, 2015 Ad Hoc reviewer, Israel Science Foundation, IL
2016 Ad Hoc reviewer, National Institutes of Aging, NIH
2016- Ad Hoc reviewer, Prostate Cancer Foundation
2017, 2020,2021 Ad Hoc reviewer, Harrington Discovery Institute
2020- Member, Life Sciences Research Foundation, US
Conference Organizer
1997 Cell Proliferation and Differentiation, University of Helsinki, Finland. September 6-8, 1997.
2000 Molecular and Cellular Targets in Cancer, University of Helsinki, Finland. September 1-2, 2000.
2002 Molecular Genesis of Cancer, Sigrid Jusélius Foundation Symposium, Espoo, Finland. June 6-9, 2002.
2004 6th NorFa p53 and Cell Cycle Workshop, Svartå, Finland. June 11-13, 2004.
2004 Molecular Mechanisms of Cancer, Biomedicum Helsinki, University of Helsinki, Finland. September 3, 2004.
2004 Imaging Technologies of Live Cells and Animals, Biomedicum Helsinki, University of
Helsinki, Finland. November 1-2, 2004.
2006 Advanced Technologies in Biological Imaging, Biomedicum Helsinki, University of
Helsinki, Finland. October 26-31, 2006.
2007 Translating the Cancer Genome, Biomedicum Helsinki, University of Helsinki, Finland. August 30-31, 2007.
2009 DNA Damage Control – from Cancer to Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. May 8, 2009.
2010 Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 18, 2010.
2011 Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 17, 2011.
2012 Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 22, 2012.
2013 Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. October 19, 2013.
RECOGNITION
Awards, honors
1989 Duodecim (Finnish Medical Society Duodecim) Literary Award
1995 Duodecim (Finnish Medical Society Duodecim) Young Investigator Award
2000 Finnish Medical Foundation 40-year Celebration Award
2001 Institut des Sciences de la Santé Europe et Médecine Junior Prize
2003 Helsinki City Science Prize
2008 The Finnish Academy of Science and Letters, Member
2014 Prostate Cancer Foundation Global Challenge Award
2014 Harrington Scholar-Innovator Award
2016 Dean’s Distinguished Lecture 2016 Johns Hopkins University
Invited talks
1986 Nordic Cancer Union: Cancer Prevention: Basic and Practical, Espoo, Finland.
1987 IX Meeting of the European Association for Cancer Research, Helsinki, Finland. “Transforming growth factor-ß regulates the proteolytic activity of cultured normal and malignant cells”.
1990 BioBio Society on Signal transduction, Helsinki, Finland. October 12, 1990. “Action of the TGF-ß growth inhibitor”.
1991 Tampere Cancer Scientists, Finnish Cancer Institute and Finnish Society for Pathology, Microbiology and Virology on Molecular mechanisms of malignant growth, Tampere, Finland. May 2-4, 1991. “Receptors and signals of TGF-ß”.
1991 Biochemical Society in Oulu, Oulu, Finland. May 29, 1991. “TGF-ß receptors and growth regulatory mechanisms”.
1992 Finnish Cancer Organizations on Gynecological Malignomas, Helsinki, Finland. February 6-7, 1992. “Growth factors and Tumor suppressor genes”.
1992 ISD on Cellular Programmes for Growth, Differentiation, and Neoplasia, Helsinki, Finland. July 19-23, 1992. “Expression human RB in mouse fibroblasts: regulation by mouse cell factors and effects on cell growth”.
1998 Biocentrum Helsinki Summer Retreat, Haikko Manor, Finland. June 1-2, 1998. “Bypass of cell cycle breaks”.
1998 Lung Cancer Symposium, Saariselkä, Finland. American College of Chest Physicians. December 3-5, 1998. “p53 mechanisms and cell cycle checkpoints in lung cancer”.
1999 Nordic p53 Workshop, NorFA, Otepää, Estonia. June 11-13, 1999. “p53 in the control of cellular UV response”.
2000 Second p53/Cell Cycle Workshop, NorFA, Lejondals Slott, Sweden. June 9-11, 2000. “Regulation of cell cycle progression”.
2001 1st International MDM2 Workshop, Dundee, Scotland. September 15-18, 2001. “Inhibition of the proteasome causes MDM2 localization to nucleoli”.
2001 32nd Nordic Haematological Spring Meeting, Vaasa, Finland. May 9-12, 2001. “Cell cycle control and tumor suppressors in hematological malignancies”.
2003 Biocentrum Helsinki Annual Day, Helsinki, Finland. November 28, 2003. “DNA damage induced cell arrest/death responses”.
2004 First IEO-IFOM Meeting on Cancer, Milan, Italy. March 11-13, 2004. “NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation”.
2004 Detection and Consequences of p53 Mutations, Kuopio, Finland. July 16-17, 2004. “DNA damage invoked p53 pathways”.
2004 12th International p53 Workshop, Dunedin, New Zealand. November 6-10, 2004. “Stress induced changes in p53 interactions”.
2005 German Cancer Research Center, Heidelberg, Germany. December 6, 2005. “p53 and the nucleolar stress response”.
2005 Finnish Cancer Organisation XXXIII Symposium, Tuusula, Finland. Februry 10-11, 2005. “Molecular changes in cancer”.
2005 Ludwig Institute for Cancer Research, Uppsala, Sweden. September 26, 2005. Biomedical Center Seminar “p53 and the nucleolar stress response”.
2005 New Frontiers in Cancer Research and Therapy, Cancer Center Karolinska, Karolinska Institute, Sweden. March 10-11, 2005. “p53 and the nucleolar stress response”.
2005 Cellular responses to DNA damage, Benzon Symposium, Cøpenhagen, Denmark. August 22-25, 2005. “NPM and PML interact in DNA damaged cells”.
2006 4th EADV Spring Symposium, Saariselkä, Finland. February 9-12, 2006. “Pathways to melanoma and the DNA damage response”.
2006 7th Bergen International Cancer Conference, Bergen, Norway. May 12-13, 2006. “p53, NPM and PML in DNA damage response and cancer”.
2006 13th International p53 Workshop, New York, NY, USA. May 20-24, 2006. “Human prostate epithelia lack DNA damage-induced p53 response and checkpoint enforcement”.
2007 National Science Week, University of Helsinki, Finland. January 12, 2007. “Barriers against cancer”.
2007 Society of Obstetrics and Gynaecology, FinnMEDI, Tampere, Finland. March 16, 2007. “Aging and cellular senescence”.
2007 Ludwig Institute for Cancer Research, Uppsala, Sweden. March 29, 2007. “Switching on the p53 response in human cancers”.
2008 Third Annual Prostate Cancer Day, Baltimore, MD. February 9, 2009. “Radiation Oncology Prostate Cancer Overview”.
2008 3rd Baltimore Area Repair Symposium, Baltimore, MD. March 27, 2008. “Aberrant DNA damage checkpoint responses of the human prostate epithelium”.
2008 EMBO Workshop on Nucleolus, Leeds, UK. June 23-26, 2008. “Tumor suppression and the nucleolus”.
2008 14th International p53 Workshop, Shanghai, China. October 31, 2008. “Identification of novel p53 pathway activating small molecule compounds”.
2009 Fourth Annual Prostate Cancer Day, Baltimore, MD. February 7, 2009. “Utilization of Prostate Tissue Cultures in Determination of Cellular DNA Damage Response”.
2009 DNA Damage Control – from Cancer to Therapeutics, Baltimore, MD. May 8, 2009. “p53 activation in cancer therapies”.
2009 Finnish Society for Oncology Annual Radiotherapy Symposium, Helsinki, Finland. May 14-15, 2009. “DNA damage response and new therapeutic approaches”.
2009 2nd GENICA/CANGENIN Genomic instability Workshop, Athens, Greece. May 16-19, 2009. “Discovery of novel topoisomerase I inhibitors through high-content screen for p53 activators”.
2009 Danish Cancer Society, Copenhagen, Denmark. October 30, 2009. “p53, DNA topology and cell stress responses”.
2010 3rd GENICA/CANGENIN/NordForsk Genomic instability Workshop, Milan, Italy. November 20-23, 2010. “DNA Damage Recognition via Activated ATM Pathway in Non-proliferating Human Prostate Tissue”.
2011 ASTRO 53rd Annual Meeting, Miami, FL. October 2-6, 2011. “Differential epithelium DNA damage response to ATM and DNA-PK pathway inhibition in human prostate tissue culture”.
2011 4th NordForsk/CANGENIN Genomic instability Workshop, Zandvoort, Netherlands. September 30- October 2, 2011. “Nucleolus as a stress response center”.
2012 5th CANGENIN Genomic instability Workshop, Barcelona, Spain. April 15-17, 2012. “Novel targeting modality for destruction of RNA Polymerase I”.
2012 Wellcome Trust Conference on Subnuclear Structures and Disease, Cambridge, UK. June 28-30, 2012. “Novel Modality to Target RNA Polymerase I”.
2013 Cold Spring Harbor Laboratory Symposium on Cancer Biology and Therapeutics, Cold Spring Harbor, NY. April 23-27, 2013. “Novel Targeting Modality for Destruction of RNA Polymerase I”.
2013 3rd NordForsk Chromatin, Transcription and Cancer Meeting, Køpenhagen, Denmark. June 26-28, 2013. “Novel Modality to Target RNA Polymerase I”.
2013 Baltimore-Philadelphia Prostate Cancer Summit, Baltimore, MD. November 1, 2013. “Novel Modality to Target RNA Polymerase I”.
2014 6th Baltimore Area Repair Symposium, Baltimore, MD. March 7, 2014. “Ribosomal RNA transcription and therapeutic targeting”.
2014 Finnish Cancer Institute on Frontiers in Translational Cancer Research, Helsinki, Finland. June 9-10, 2014. “Ribosomal RNA Transcription and its Cancer Therapeutic Targeting”
2014 16th International p53 Workshop, Stockholm, Sweden. June 15-19, 2014. “Therapeutic Targeting of RNA Pol I”.
2014 International Conference on Transcription by RNA Polymerases I, III, IV, and V, Ann Arbor, Michigan. June 19-24, 2014. “Therapeutic Targeting of RNA Pol I”.
2014 4th NordForsk Chromatin, Transcription and Cancer Meeting, Hverageroi, Iceland. August 27-29, 2014. “RNA Polymerase I intervention therapies in cancer”.
2015 Eight Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL. March 15-17, 2015. “Targeting RNA Polymerase I”.
2015 Harrington Discovery Institute 3rd Annual Scientific Symposium, Cleveland, OH. May 20-21, 2015. “A novel approach to treat cancer: RNA polymerase I inhibition”.
2016 International Conference on Transcription by RNA Polymerases I, III, IV, and V, Ann Arbor, Michigan. June 24-28, 2016. “Targeting of RNA Pol I activates a novel transcription elongation checkpoint”.
2017 ASBMB Special Symposia Series Emerging Roles for the Nucleolus, Kansas City, Missouri. October 26-29, 2017. “Targeting of RNA Pol I activates a novel transcription elongation checkpoint”.
2017 Prostate Cancer Research Day, Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. December 7, 2017. “Lipids Meet RNA Production – a New Paradigm”.
2018 International Conference on Transcription by RNA Polymerases I, III, IV, and V, Toulouse, France. June 26-29, 2018. “Translation of small molecule inhibitors of RNA Pol I transcription as a therapeutic approach for cancer treatment”.
2019 Twelfth Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL. March 3-5, 2019. “RNA Polymerase I and its therapeutic targeting”.
2019 ASBMB Special Symposia Series Emerging Roles for the Nucleolus, Kansas City, Missouri. October 24-27, 2019. “Therapeutic targeting of RNA Pol I in cancer”.
Research seminars
1991 Laakso Hospital, Helsinki, Finland. March 8, 1991. “Oncogenes and tumor suppressor genes”.
1991 Finnish Red Cross, Helsinki, Finland. December 4, 1991. “Transforming growth factor-ß control of cell growth and proteolysis”.
1992 Department of Clinical Chemistry, Helsinki University Central Hospital. March 6, 1992. “TGF-ß growth regulatory effects”.
1992 Department of Biochemistry, University of Helsinki, Finland. February 14, 1992. “Transforming growth factor-ß and the retinoblastoma gene product in growth control”.
1995 Department of Pathology, University of Helsinki, Finland. March 14, 1995. “Tumor suppressor genes and their action”.
1997 Turku Immunology Center, Turku, Finland. February 5, 1997. “p53 in DNA damage control and cell cycle”.
1998 Department of Clinical Chemistry, Helsinki University Central Hospital. March 13, 1998. “p53 tumor suppressor protein actions in the control of DNA damage and cell cycle”.
2000 AIVirtanen Institute, University of Kuopio, Kuopio, Finland. March 13, 2000. “Cell cycle control by growth factors”.
2000 Biocity Turku, Turku, Finland. November 8, 2000. “Growth factors in cell cycle control”.
2000 Department of Pathology, University of Helsinki, Finland. November 14, 2000. “Role of p53 pathway in tumor biology”.
2001 Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland. October 10, 2001. “Role of p53 in skin cancer”.
2002 Institute of Medical Technology, University of Tampere, Finland. March 13, 2002. “Transcriptional control by p53”.
2002 Developmental and Reproductive Biology Program, Biomedicum Helsinki, Finland. November 26, 2002. “UV damage induced transcriptional and cellular responses”.
2003 Nordea Research Seminar in Biomedicine, Biomedicum Helsinki, Finland. September 23, 2003. “Genetic changes in cancer”.
2005 Biocity Turku, Turku, Finland. February 3, 2005. “p53 and the nucleolar stress response”.
2006 Drug Discovery and Development Center, University of Helsinki, Finland. November 7, 2006. “The p53 pathway as a therapeutic target”.
2007 Department of Urology, Helsinki University Central Hospital, Finland. February 2, 2007. “Prostate DNA damage responses”.
2007 Neurobiology Research Program, Biomedicum Helsinki, Finland. February 7, 2007. “DNA damage, cell senescence and cancer”.
2007 Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD. April 23, 2007. “Switching on the p53 response in human cancers”.
2007 Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. November 20, 2007. “DNA damage responses in the prostate”.
2008 Translational Research Conference, The Johns Hopkins University School of Medicine, Baltimore, MD. December 10, 2008. “p53 and DNA topology”.
2009 Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 5, 2009. “p53 Pathway in Cancer Therapy”.
2009 ICMIC Seminar Series, The Johns Hopkins University School of Medicine, Baltimore, MD. September 9, 2009. “Visualizing cell stress responses in organelles, cells and tissues”.
2010 Breast Cancer Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. January 12, 2010. “p53, DNA topology and cellular stress response”.
2010 IVth Quarter, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. April 12, 2010. “DNA damage pathways in cancer”.
2010 Department of Radiation Oncology, Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, MD. May 17, 2010. “Discovery of small-molecule compounds”.
2010 Chemical Therapeutics Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. May 17, 2010. “Discovery and mechanisms of novel small-molecule compounds”.
2010 Department of Urology, Stanford University, San Francisco, CA. November 4, 2010. “New insights into p53 pathway as a therapeutic target”.
2010 NYU Cancer Institute, New York University, New York, NY. December 15, 2010. “New insights into p53 pathway as a therapeutic target”.
2011 Chemical Therapeutics Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. June 15, 2010. “New insights into p53 pathway as a therapeutic target”.
2011 Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD. December 6, 2011 “DNA Damage Responses in Differentiated Tissues”.
2012 Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. February 25, 2012. “Novel small-molecule regulators of androgen receptor activity in prostate cancer”.
2012 Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD. February 28, 2012. “Nucleolus as a stress response center”.
2012 Institute of Biotechnology, University of Helsinki, Helsinki, Finland. September 12, 2012. “Nucleolus as a stress response center”.
2012 Department of Molecular Biology and Genetics, The Johns Hopkins University School of Medicine, Baltimore, MD. October 18, 2012. “Nucleolus as a stress response center and therapeutic target”.
2012 Life Sciences Summit, New York, NY. December 13, 2012. “A novel anticancer compound”.
2013 Alliance for Science & Technology Development, Baltimore, MD. February 19, 2013. “A novel approach to treat cancer: RNA Polymerase I inhibition”.
2013 Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. March 2, 2013. “RNA Polymerase I inhibition as a Strategy to Curb Prostate Cancer”.
2013 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC. April 12, 2013. “The Nucleolus as a Stress Response Center and Therapeutic Target”.
2013 Cytostasis to Metastasis, Memorial Sloan-Kettering Cancer Center, New York, NY. April 26, 2013. “The Nucleolus as Therapeutic Target”.
2013 Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 7, 2013. “Novel Intervention Approaches to Treat Cancer”.
2013 Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. September 11, 2013. “DNA damage – from signals to repair and back again”.
2014 Department of Biochemistry and Molecular Genetics/UAB Stem Cell Institute, University of Alabama, Birmingham, AL. August 18, 2014. “Ribosomal RNA Transcription and its Cancer Therapeutic Targeting”.
2014 University of Dundee, Scotland, UK. September 9, 2014. “Therapeutic Targeting of RNA Polymerase I in Cancer”.
2014 Translational Research Conference, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. September 24, 2014. “The Nucleolus, RNA Polymerase I and its Cancer Therapeutic Targeting”.
2015 Wednesday Seminars, National Institute of Aging, Baltimore, MD. March 11, 2015. “The Nucleolus, RNA Polymerase I and its Cancer Therapeutic Targeting”.
2015 Department of Radiation Oncology, Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, MD. July 21, 2015. “RNA Polymerase I and its Cancer Therapeutic Targeting”.
2016 The Johns Hopkins University School of Medicine, Baltimore, MD. May 4, 2016. Dean's Distinguished Lecture 2016: “New Targets and New Molecules for Cancer: RNA Polymerase I Program”.
2016 Institute of Biotechnology Annual Retreat, University of Helsinki, Helsinki, Finland. May 19, 2016. “RNA Polymerase I Program”.
2016 BMB Training Program, School of Public Health, The Johns Hopkins University School of Medicine, Baltimore, MD. September 23, 2016. “New Targets and New Molecules for Cancer: RNA Polymerase I Program”.
2016 Molecular Radiation Sciences Progress Report Seminar, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. September 29, 2016. “Research reproducibility and rigor: Practices and practical examples”.
2017 Cancer Chemical and Structural Biology Program, The Johns Hopkins University School of Medicine, Baltimore, MD. January 24, 2017. “New Targets and New Molecules for Cancer: RNA Polymerase I Program”.
2017 Institute of Biotechnology, University of Helsinki, Helsinki, Finland. January 26, 2017. “RNA Polymerase I Program”.
2017 Biomedicum Helsinki Seminars, University of Helsinki, Helsinki, Finland. January 30, 2017. “RNA Polymerase I Program”.
2017 39th Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 8, 2017. “RNA Polymerase I Program – New Targets and New Molecules for Cancer”.
2017 Department of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD. September 20, 2017. “RNA Polymerase I and its Cancer Therapeutic Targeting”.
2018 Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. February 14, 2018. “Biology and strategies to target RNA polymerase I in cancer”.
2018 Department of Biochemistry and Molecular Genetics Colloquim, University of Virginia, Charlottsville, VA. March 1, 2018. “RNA Polymerase I and its Therapeutic Targeting”.
2018 EMBL Blue Seminar, EMBL, Heidelberg, Germany. March 5, 2018. “Biology and strategies to target RNA polymerase I in cancer”.
2018 Translational Research Conference, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. October 17, 2018. “Biology and strategies to target RNA polymerase I in cancer”.
2018 Laval University, Quebec, Canada. October 12, 2018. “Biology and strategies to target RNA polymerase I in cancer”.
2019 Department of Biophysics, The Johns Hopkins University School of Medicine, Baltimore, MD. October 16, 2019. “Biology and strategies to target RNA polymerase I in cancer”.
2019 Molecular Radiation Sciences Progress Report Seminar, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. October 17, 2019. “Data Management and Retention Research Integrity Seminar”.
2020 IVth Quarter, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. March 16, 2020. “New Cancer Drug Discovery”.
2020 BMB Cancer Biology Course, The Johns Hopkins University School of Public Health, Baltimore, MD. May 6, 2020. “New Cancer Drug Discovery”.
2020 Proton Therapy Course, Department of Radiation Oncology, The Johns Hopkins Proton Therapy Center, Washington DC. October 9, 2020. “Biology of Proton Effects”.
2020 Molecular Radiation Sciences Progress Report Seminar, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. October 20, 2020. “Data Management and Retention Research Integrity Seminar”.
2021 Department of Radiation Oncology, Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, MD. January 28, 2021. “New Cancer Drug Discovery”.
Other Professional Accomplishments
Declared qualified for the following posts
1995 Professor of Cell Biology, University of Jyväskylä (ranked 2nd)